Congo’s Ebola map expands to seven provinces

Congolese surveillance figures reported by Reuters crossed two thresholds in the same week: 7,022 confirmed Ebola cases and 3,398 deaths across 62 health zones by 10 September, and a first confirmed case in Sud-Ubangi, a province in the far northwest hundreds of kilometres from the eastern regions where the outbreak began. That makes seven provinces affected. WHO's most recent disease-outbreak report, covering data through 7 September, recorded a lower total of 6,479 cases, a gap that reflects the lag between provincial tallies and WHO's own verification cycle rather than a disagreement about scale.

The numbers, already large, likely understate reality. WHO's emergency committee judged in late August that the true number of infections could be three to four times the detected count, because many cases in remote or conflict-affected areas are never found.

A river-boat journey no one tracked

The Sud-Ubangi case shows how the virus can travel undetected. According to RFI, a 23-year-old man left South Kivu in July, crossed Rwanda and Uganda, re-entered Congo through Ituri, was hospitalised after a road accident in Kisangani, and then boarded a Congo River boat heading northwest. He developed symptoms somewhere along the route, received care from a nurse on the vessel, and died after reaching Akula. Ebola was confirmed only from a post-mortem sample.

That journey spanned multiple provinces and potentially three countries before anyone knew he was infected. Response teams must now reconstruct every possible exposure along the route: hospitals, boats, informal clinics, family members. Thirty-eight contacts had been identified near the death site, a provisional count. Sud-Ubangi also borders the Central African Republic, requiring cross-border alerting even though there is no evidence the patient entered CAR.

Ebola spreads through direct contact with the bodily fluids of a sick or dead person. It is not airborne. Containment depends on finding every infected person quickly, isolating them, and monitoring everyone they touched for 21 days. Think of the contact list as the response's early-warning system: when patients appear who were never on it, the virus has outrun the teams tracking it.

No proven vaccine for this strain

Previous Ebola outbreaks in Congo were caused by Zaire ebolavirus. This one is caused by Bundibugyo virus, a different species. The distinction matters because Ervebo, the vaccine approved by the US FDA for Zaire ebolavirus, targets a surface protein specific to that species. Whether it offers any protection against Bundibugyo in humans has not been demonstrated. WHO allocated 70,000 Ervebo doses for research use, with 2,007 people vaccinated by 7 September under a protocol that tells recipients protection is unproven.

A clinical trial called PARTNERS is testing two experimental treatments, MBP134 and remdesivir, in over 300 enrolled patients. Enrollment is underway; neither treatment has demonstrated efficacy yet. Bundibugyo-specific vaccines from Oxford and Moderna are in early safety trials in the UK and Canada.

Congo has scaled treatment capacity from a single nine-bed centre in May to 59 facilities with 1,346 beds by September. A revised 180-day response plan seeks roughly $1.3 billion.

For European readers wondering about imported risk: WHO's 7 September report recorded one case in France and two patients transferred to Germany for treatment. The outbreak's trajectory will be determined by what happens inside Congo, where a virus with no proven vaccine is moving through a geography that makes tracing every contact close to impossible. The evidence that containment is gaining ground has yet to arrive.